Semaglutide pilot links six-month therapy to shifts in eight microRNAs

The wire

1. 01In a prospective observational pilot, 31 adults with obesity on 0.25 mg to 1.5 mg weekly semaglutide gave plasma samples at baseline and six months; eight miRNAs changed nominally significantly.
2. 02The work probes a possible molecular mechanism behind GLP-1 receptor agonist effects, an area the authors say has no prior human data in obesity.
3. 03No association held after FDR correction, the cohort is small and uncontrolled, and doses were submaximal, so the findings are hypothesis-generating only.

From the source

The effect of submaximal doses of semaglutide on the expression of micro-RNA in patients with obesity: a pilot study

Obesity facts · 2026 Oct 1 · Jurica J, Miertova Z, Pec MJ et al.